Johns Hopkins University, Johns Hopkins Medicine
100 papers in the library · 21,304 citations · publishing 1986-2025
JAMA Psychiatry October 1, 2022 David B. Yaden, James B. Potash, Roland R. Griffiths 153 citations
This Viewpoint presents impediments to the clinical application of psychedelics created by extreme shifts in public perception while advocating further study and encouraging the dispute of claims not supported by available evidence.
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees October 1, 2022 David B. Yaden, Brian D. Earp, Roland R. Griffiths 31 citations
Evidence suggests that psychedelics bring about their therapeutic outcomes in part through the subjective or qualitative effects they engender and how the individual interprets the resulting experiences. However, psychedelics are contraindicated for individuals who have been diagnosed with certain mental illnesses, on the grounds that these subjective effects may be disturbing or otherwise...
Neuropharmacology September 15, 2022 S Ross, M Agrawal, Roland R. Griffiths et al. 69 citations
Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are associated with poor medical and psychiatric outcomes. Currently available treatment modalities in this patient population, including medication and psychotherapy, are limited in effectiveness, especially regarding existential distress. The lack of...
PLoS One August 24, 2022 Mary M. Sweeney, Sandeep M. Nayak, Ethan Hurwitz et al. 60 citations
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by...
Neuropharmacology August 17, 2022 Jack E Henningfield, Marion A Coe, Roland R. Griffiths et al. 34 citations
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...
Scientific Reports May 24, 2022 David Wyndham Lawrence, Robin Carhart-Harris, Roland R. Griffiths et al. 64 citations
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system pathology. A qualitative analysis was conducted of all N, N-DMT experiences posted to the r/DMT Reddit community over a 10-year period from 2009 to...
Research Square April 28, 2022 David Wyndham Lawrence, Robin Carhart-Harris, Roland R. Griffiths et al. 2 citations
Abstract Background: Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system pathology. Methods: Qualitative analysis of all N, N-DMT experiences posted to the r/DMT Reddit community over a 10-year period...
Frontiers in Psychology March 28, 2022 Sandeep M. Nayak, Roland R. Griffiths 76 citations
Introduction Although the topic of consciousness is both mysterious and controversial, psychedelic drugs are popularly believed to provide unique insights into the nature of consciousness despite a lack of empirical evidence. Methods This study addresses the question of whether psychedelics change the attribution of consciousness to a range of living and non-living entities. A survey was...
Journal of Psychopharmacology February 1, 2022 Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. 419 citations
Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...
Frontiers in Neuroergonomics January 20, 2022 Yun Zhou, Frederick S. Barrett, Theresa M. Carbonaro et al. 17 citations
Psilocybin (a serotonin 2A, or 5-HT 2A , receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with the selective 5-HT 2A receptor inverse agonist radioligand [ 11 C]MDL 100,907 (a.k.a. M100,907) and cortical regions of interest (ROIs) derived from resting-state functional...
Current Topics in Behavioral Neurosciences 2022 David B. Yaden, Sandeep M. Nayak, Natalie Gukasyan et al. 31 citations
End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these contexts remain limited. In particular, psychological factors such as depression, existential distress, and well-being remain challenging to address with current medications. Here, we review recent research on the use of psychedelics in clinical...
Translational Psychiatry November 8, 2021 Manoj K. Doss, Michal Považan, Monica D Rosenberg et al. 343 citations
Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin...
Brain October 22, 2021 Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis et al. 196 citations
Abstract Classic psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have recaptured the imagination of both science and popular culture, and may have efficacy in treating a wide range of psychiatric disorders. Human and animal studies of psychedelic drug action in the brain have demonstrated the involvement of the serotonin 2A (5-HT2A) receptor and the cerebral cortex in...
Pharmacopsychiatry August 4, 2021 Sandeep M. Nayak, Natalie Gukasyan, Frederick S. Barrett et al. 67 citations
Abstract Introduction Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psychedelic trials. There is limited information on the use of classic psychedelics (e. g., LSD or psilocybin) in individuals using mood stabilizers to treat bipolar disorder. This is important to know, as individuals with bipolar depression may...
The International Journal of Neuropsychopharmacology May 10, 2021 Natalie Gukasyan, David B. Yaden, Matthew W. Johnson et al. 56 citations
Abstract Psychedelic substances produce unusual and compelling changes in conscious experience that have prompted some to propose that psychedelics may provide unique insights explaining the nature of consciousness. At present, psychedelics, like other current scientific tools and methods, seem unlikely to provide information relevant to the so-called “hard problem of consciousness,” which...
JAMA Psychiatry May 1, 2021 David B. Yaden, Mary E. Yaden, Roland R. Griffiths 102 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
Journal of Psychopharmacology February 20, 2021 Albert Garcia‐romeu, Frederick S. Barrett, Theresa M. Carbonaro et al. 101 citations
Background: Growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose....
JAMA Psychiatry February 10, 2021 Alan K. Davis, Roland R. Griffiths 3 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
Journal of Psychoactive Drugs February 3, 2021 Bhanu Sharma, David W. Lawrence, Roland R. Griffiths et al. 37 citations
This study was designed to identify trends in the top-cited classic psychedelic publications. The top 50 publications on classic psychedelics with the greatest total of number of citations and annual citation rate were identified and pooled. Unique articles (n = 76) were dichotomized by median year of publication (2010.5); the differential distribution of study characteristics between the...
Journal of Psychopharmacology January 9, 2021 Alan K. Davis, Frederick S. Barrett, Sara So et al. 166 citations
Background: Several measures have been developed to examine acute psychedelic effects (e.g. mystical-type and challenging experiences), but no measure assesses acute psychologically insightful experiences that may occur during psychedelic experiences. Aim: The purpose of this study was to develop and examine the psychometric properties of the Psychological Insight Questionnaire. Method: A...
ACS Pharmacol Transl Sci December 10, 2020 David B. Yaden, Roland R. Griffiths 534 citations
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not...
JAMA Psychiatry November 4, 2020 Mary P Cosimano, Alan K. Davis, Frederick S. Barrett et al. 1,269 citations
Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: To investigate the effect of...
Scientific Reports October 2, 2020 Manoj K. Doss, Darrick G. May, Matthew W. Johnson et al. 52 citations
Abstract Salvinorin A (SA) is a κ-opioid receptor agonist and atypical dissociative hallucinogen found in Salvia divinorum . Despite the resurgence of hallucinogen studies, the effects of κ-opioid agonists on human brain function are not well-understood. This placebo-controlled, within-subject study used functional magnetic resonance imaging for the first time to explore the effects of inhaled...
Neuroimage September 1, 2020 Frederick S. Barrett, Samuel R Krimmel, Roland R. Griffiths et al. 191 citations
Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders. Psilocybin induces widespread dysregulation of cortical activity, but circuit-level mechanisms underlying this effect are unclear. The claustrum is a subcortical nucleus that highly expresses...
Journal of psychopharmacology (Oxford, England) September 1, 2020 Alan K. Davis, John Clifton, Eric G Weaver et al. 144 citations
Experiences of having an encounter with seemingly autonomous entities are sometimes reported after inhaling N,N-dimethyltryptamine. The study characterized the subjective phenomena, interpretation, and persisting changes that people attribute to N,N-dimethyltryptamine-occasioned entity encounter experiences. Two thousand, five hundred and sixty-one individuals (mean age 32 years; 77% male)...